Tirzepatide vs Semaglutide: Complete Comparison Guide

Two Medications, One Decision

If you've started looking into GLP-1 medications for weight loss, you've encountered the two names that dominate the conversation: semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). They're often discussed in the same breath — and for good reason. Both deliver meaningful, sustained weight loss for most patients who tolerate them. Both work primarily through gut hormone signaling. Both are weekly injections.

But they are not the same molecule, they don't act on the same receptors, and the choice between them genuinely matters. This guide is the head-to-head comparison patients keep asking for — without sales spin, without oversimplification, and with the practical detail you need to have an informed conversation with your provider.

The Quick Answer for People Skimming

For most patients without contraindications, current head-to-head clinical evidence suggests tirzepatide produces somewhat greater average weight loss than semaglutide at the highest approved doses. Tirzepatide's average weight loss in the SURMOUNT-1 trial reached approximately 20.9% of body weight at 72 weeks on the 15 mg dose; semaglutide's STEP 1 trial showed roughly 14.9% at 68 weeks on the 2.4 mg dose. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist.

That said: tolerability, cost, dose responsiveness, and goals matter at least as much as the headline number — and many patients reach their goals on either medication. Read on for the actual comparison.

Mechanism: One Receptor vs Two

This is the core scientific difference and it explains a lot of the rest of the comparison.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released from the gut after eating. By activating GLP-1 receptors, semaglutide increases insulin secretion when blood glucose is elevated, suppresses glucagon, slows gastric emptying, and signals satiety in the brain's appetite-control centers. The net effect is reduced hunger, reduced "food noise," and steadier blood sugar.

Tirzepatide is a dual agonist. It activates the same GLP-1 receptor that semaglutide does — and it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone with complementary effects on insulin secretion and lipid metabolism. The combined effect on both receptors is part of why tirzepatide tends to produce greater weight loss in head-to-head data: you're activating two appetite-and-metabolism pathways instead of one.

Important nuance: more receptors does not automatically mean better for every patient. Some people respond beautifully to semaglutide and don't need a dual agonist. Others tolerate tirzepatide better, or vice versa. Mechanism informs expectations; it doesn't dictate outcomes.

Efficacy: The Clinical Trial Numbers

The cleanest way to compare efficacy is to look at the pivotal weight-loss trials for each drug.

• Semaglutide — STEP 1 (2021): Adults with obesity (without diabetes) on semaglutide 2.4 mg weekly lost an average of approximately 14.9% of body weight at 68 weeks, vs 2.4% on placebo.
• Tirzepatide — SURMOUNT-1 (2022): Adults with obesity (without diabetes) on tirzepatide lost an average of approximately 15.0%, 19.5%, and 20.9% of body weight on the 5 mg, 10 mg, and 15 mg weekly doses respectively at 72 weeks, vs 3.1% on placebo.
• Head-to-head (SURMOUNT-5, 2025): A direct comparison of tirzepatide vs semaglutide at maximum doses for weight loss reported greater mean weight reduction with tirzepatide.

For weight-loss expectations specifically: roughly two-thirds of patients on tirzepatide 15 mg in SURMOUNT-1 lost ≥20% of their body weight; roughly one-third on semaglutide 2.4 mg in STEP 1 lost ≥20%. Both numbers are dramatic compared to lifestyle-only weight loss programs, and both are a function of dose, adherence, and individual response.

Translation: the average tirzepatide patient on the highest dose tends to lose more weight than the average semaglutide patient on the highest dose. The average is not every. People are not averages.

Side Effects: What Patients Actually Experience

Both medications share the same primary side effect category: gastrointestinal. Nausea, occasional vomiting, constipation or diarrhea, reflux, and reduced appetite are common — especially during the first 4–8 weeks of dose escalation. For most patients, these effects fade as the body adjusts.

In aggregate clinical data, side effect profiles are broadly similar between the two medications, with tirzepatide showing slightly higher rates of GI effects in some trial arms — likely related to the steeper appetite suppression and weight loss. The rate of patients discontinuing due to side effects in both pivotal trials was modest (roughly 4–7% of treated patients).

What helps in practice:

• Slow titration: Faster escalation is associated with worse side effects. Many providers (including ours) titrate more conservatively than the FDA label allows.
• Hydration and protein intake: Adequate water and protein meaningfully reduce nausea and constipation.
• Smaller, more frequent meals: Slowed gastric emptying is the mechanism — eating accordingly is the workaround.
• Anti-nausea support: Short courses of ondansetron or other supportive medications can be used during early titration if needed.

Both medications carry a boxed warning for risk of thyroid C-cell tumors (based on rodent studies) and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Both also carry warnings for pancreatitis, gallbladder disease, severe GI events, and acute kidney injury related to dehydration. A licensed provider should review your full medical history before prescribing either one.

Dosing Schedules

Both medications are weekly subcutaneous injections, typically rotated through the abdomen, thigh, or upper arm. The dose schedules are different.

Microdose protocols — starting at substantially lower doses than the standard 0.25 mg semaglutide or 2.5 mg tirzepatide — are increasingly common in compounded formulations for patients who want a gentler approach or are sensitive to side effects. We've covered microdose GLP-1 strategies in detail in our microdose GLP-1 article.

Cost: Where the Real-World Gap Opens Up

Cash-pay pricing is where the practical decision often gets made.

Why the difference between compounded semaglutide and compounded tirzepatide pricing? Active pharmaceutical ingredient (API) cost is the biggest driver — tirzepatide API has historically been more expensive at the wholesale level than semaglutide API. The dose magnitudes (mg per week) are also different, which affects how much API is in each vial. We've written more about the regulatory framework around compounded GLP-1s in our piece on compounded vs brand-name semaglutide.

Which One Is Right for You?

This decision should be made with a licensed provider who knows your full history. That said, here's how the choice often plays out.

Semaglutide may be the better fit if:

• Your weight-loss goal is moderate and you don't need the highest possible average reduction
• Cost is a primary consideration and the lower-priced option matters
• You've previously tolerated or responded well to GLP-1 therapy
• You want a microdose / gentle protocol — semaglutide has the most established microdose practice
• You and your provider prefer a single-mechanism agent

Tirzepatide may be the better fit if:

• Your weight-loss goal is significant (e.g., >15–20% of body weight) and average outcomes are an important factor
• You've tried semaglutide and plateaued before reaching your goal
• You have type 2 diabetes or insulin resistance and your provider feels GIP activity may help
• You're willing and able to invest in higher monthly cost for somewhat greater average efficacy
• You don't have specific contraindications to either medication

Some patients also switch between them — starting on one, achieving partial results, and transitioning to the other. That's a clinical decision; both medications have specific titration considerations when used in sequence and shouldn't be self-managed.

What "Tirzepatide vs Semaglutide for Weight Loss" Comes Down To, Honestly

If we had to summarize the comparison in a few sentences, it would be this: tirzepatide's two-receptor mechanism produces somewhat greater average weight loss in clinical trials than semaglutide's single-receptor mechanism, especially at maximum doses. The cost of that extra efficacy — both literally and in terms of average GI tolerability — is real but not enormous. For some patients, semaglutide is the right answer. For others, tirzepatide is. For many, either would work and the choice is shaped by cost, dose preference, and the specific goal.

The "best" GLP-1 isn't a fixed answer — it's the one that gets you to your goal at a dose you tolerate, at a price you can sustain, with a provider who actually adjusts the protocol based on how you're doing. That last variable is the one that gets undersold in the marketing for either medication, and it's the variable that matters most over a 12- to 18-month treatment course.

Tirzepatide Weight Loss Results in the Real World

Outside of clinical trials, real-world results vary more widely than the trial averages suggest. Most patients on properly titrated tirzepatide who reach a maintenance dose of 10–15 mg weekly and who maintain reasonable nutritional and movement habits see body-weight changes in the range of 12% to 22% over 9 to 18 months. Patients who skip doses, plateau-stuck on starter doses without titrating, or stop the medication early often see less.

The single biggest predictor of long-term success on either medication is not which one you chose — it's whether you stay on the appropriate dose long enough, with the right protein intake and movement, and whether you have a plan for what happens after maintenance.

Where Madison Meds Fits

We offer both compounded semaglutide and compounded tirzepatide programs through licensed U.S. compounding pharmacies. Each prescription is reviewed by a licensed provider after a full medical intake. Pricing is bundled (consult, medication, shipping) and transparent.

• Compounded Semaglutide — from $169/month (microdose from $125/month)
• Compounded Tirzepatide — from $289/month (microdose from $165/month)

Our providers will help you choose between them based on your goals, history, and budget — and adjust the plan over time. There is no penalty for starting on one and switching, and there is no pressure to escalate to a higher dose than you actually need.

Compounded medications are not FDA-approved drugs. Individual results vary. A licensed provider will review your medical history before prescribing, and not all patients are appropriate candidates for GLP-1 therapy. The trial percentages cited in this article reflect mean values from published Phase 3 studies (STEP 1, SURMOUNT-1, SURMOUNT-5) and do not predict individual outcomes. This article is for educational purposes and does not constitute medical advice.